Rialto Wealth Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Rialto Wealth Management’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-122	Closed	-$551	–	1796
2025 Q2	$551	Buy	+122	New	+$548	﹤0.01%	1105

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rialto Wealth Management's YMAB Position: Q3 2025 in Review

Rialto Wealth Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 122 shares — an estimated $551 sold.

Rialto Wealth Management first reported a position in YMAB in Q2 2025 and held it in 1 quarter. The position peaked at $551 in Q2 2025. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Rialto Wealth Management reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Rialto Wealth Management sold 122 Y-mAbs Therapeutics shares in Q3 2025, an estimated $551.
Rialto Wealth Management first reported a position in Y-mAbs Therapeutics in Q2 2025 and held it in 1 quarter.
Rialto Wealth Management's Y-mAbs Therapeutics position peaked at $551 in Q2 2025.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Rialto Wealth Management's 13F filing for Q3 2025, filed 7 Nov 2025.